AcelRx Pharmaceuticals‘ NDA for Zalviso was accepted for filing by the FDA. The acceptance indicates the FDA has determined that the application is sufficiently complete to permit a substantive review. The NDA, submitted on September 27, 2013, seeks approval for the marketing and sale of Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting. The NDA submission is based primarily on data from a Phase III registration program that included two...